 |
 |
|
 |
Home  Protein Biomarkers |
|
| |
 Protein Biomarkers
|
| |
| Diagnosis is one of the most critical links in medicine today. Timely, accurate diagnosis can mean the difference between patient admission and discharge, between relief of symptoms and prolonged suffering between early intervention and missed therapeutic opportunities and, in the gravest instances between life and death. It is particularly true when Sepsis patients are treated with Xigris® from Lilly, which is human recombinant protein C for anticoagulation and inflammation. The drug has caused major side affect, such as bleeding if the dose is not right for the patient. Therefore, each patient needs to test his or her protein C concentration from blood before the treatment with Xigris®. |
| Striving for sustained growth, DiaCarta has adopted a strategy that encompassed the diagnostic continuum from molecular testing to protein biomarker measurements. Through combined expertise in molecular testing and protein biomarker assay development, we are able to select large market opportunities, access potential markets of disease, identify proteins with high diagnostic utility, apply validated disease markers to advanced testing platforms, bring products to market, and educate physicians and other clinicians on new approaches to diagnosis, thereby benefiting patients. |
| DiaCarta has expertise in rapid, high-capacity antibody development, enabling high throughput screening of potential diagnostic markers and cost-efficient development of high affinity antibodies for use in commercialized products. |
 |
 |
Blood coagulation and the protein C anticoagulation pathway. |
 |
|
 |
